Lifetime Costs of Medical Care After Heart Failure Diagnosis

Dunlay, Shannon M.; Shah, Nilay D.; Shi, Qian; Morlan, Bruce W.; VanHouten, Holly; Long, Kirsten Hall; Roger, Véronique L.

doi:10.1161/circoutcomes.110.957225

Cited by 229 publications

(211 citation statements)

References 23 publications

Supporting

Mentioning

198

Contrasting

Unclassified

Order By: Relevance

“…HF is an enormous economic burden for health care system and the most common reason for hospitalization of people over 65 years of age [8,17]. Unless appropriate preventive strategies and measures are implemented instantly, the prevalence, related complications and total burden of HF and especially in older population, will expand and tax future healthcare systems even more [18].…”

Section: Socio-economic Challengesmentioning

confidence: 99%

Heart failure: A challenging syndrome for health care professionals

Lambrinou¹,

Protopapas²,

Kalogirou³

2018

Cardiovasc Disord Med

View full text Add to dashboard Cite

Research and evidence-based practice in heart failure (HF) have well been developed the latest years helping health professionals to cope with multiple care needs of patients with HF. The current review presents an overview of the challenging issues of health professionals who care for patients with HF. The review was based on the relevant databases of PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Cochrane Library (reviews and clinical trials). Mortality and impaired quality of life in patients with HF still rises. This is mainly due to the ageing of population and the fact that prevalence of HF is higher in older people. Often HF in order people exists with co-morbidities which make HF diagnosis and management more difficult and complex.

show abstract

Section: Socio-economic Challengesmentioning

confidence: 99%

Heart failure: A challenging syndrome for health care professionals

Lambrinou¹,

Protopapas²,

Kalogirou³

2018

Cardiovasc Disord Med

View full text Add to dashboard Cite

show abstract

“…The annual costs of HF are currently estimated at $30.7 billion 2, 3. More than two thirds of these costs can be attributed to the costs associated with hospitalization 4. For Medicare patients, 30‐day readmission rates are as high as 25% and HF is the leading cause of rehospitalization 5…”

Section: Introductionmentioning

confidence: 99%

Cost‐Effectiveness of Ivabradine for Heart Failure in the United States

Kansal

Cowie

Kielhorn

et al. 2016

JAHA

View full text Add to dashboard Cite

BackgroundIvabradine is a heart rate–lowering agent approved to reduce the risk of hospitalization for worsening heart failure. This study assessed the cost‐effectiveness of adding ivabradine to background therapy in the United States from the perspective of a commercial or Medicare Advantage payer.Methods and ResultsA cost‐effectiveness, cohort‐based Markov model using a state transition approach tracked a cohort of heart failure patients with heart rate ≥70 beats per minute in sinus rhythm who were treated with ivabradine+background therapy or background therapy alone. Model inputs, including adjusted hazard ratios, rates of hospitalization and mortality, adverse events, and utility‐regression equations, were derived from a large US claims database and SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial). In the commercial population, ivabradine+background therapy was associated with a cost savings of $8594 versus the cost of background therapy alone over a 10‐year time horizon, primarily because of reduced hospitalization. Ivabradine was associated with an incremental benefit of 0.24 quality‐adjusted life years over a 10‐year time horizon. In the Medicare Advantage population, the incremental cost‐effectiveness ratio for ivabradine was estimated to be $24 920/quality‐adjusted life years.ConclusionsThe cost‐effectiveness model suggests that for a commercial population, the addition of ivabradine to background therapy was associated with cost savings and improved clinical outcomes. For a Medicare Advantage population, the analysis indicates that the clinical benefit of ivabradine can be achieved at a reasonable cost.

show abstract

“…Assim, diversos autores estudaram o impacto econômico da IC buscando revisões econômicas em saúde, análises de custo-efetividade de drogas em ensaios clínicos e em registros, e análises econômicas de gastos em saúde 8,9,81,11 . Shannon e col. realizaram estudo que avaliou …”

Section: Custos De Internação Hospitalarunclassified

Análise de dados de pacientes internados por insuficiência cardíaca descompensada - impacto sobre desfechos clínicos e custos

Abuhab¹

View full text Add to dashboard Cite

show abstract

Lifetime Costs of Medical Care After Heart Failure Diagnosis

Cited by 229 publications

References 23 publications

Heart failure: A challenging syndrome for health care professionals

Heart failure: A challenging syndrome for health care professionals

Cost‐Effectiveness of Ivabradine for Heart Failure in the United States

Análise de dados de pacientes internados por insuficiência cardíaca descompensada - impacto sobre desfechos clínicos e custos

Contact Info

Product

Resources

About